Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

ale patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen.

Contraindications

PEGINTRON is contraindicated in patients with known hypersensitivity reactions such as urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. PEGINTRON/REBETOL combination therapy is additionally contraindicated in women who are pregnant or may become pregnant (see Boxed Warning and Pregnancy section), men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL per min.

Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. If this drug is used during pregnancy or if a patient becomes pregnant, the patient should be apprised of the potential hazard to a fetus. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 The U.S. Food and Drug ... today voted 12 yes, 4 no, and 1 abstention ... observed risks to support the use of CRESTOR® (rosuvastatin ... Men greater than or equal to 50 years, women ... Fasting LDL < 130 mg/dL; hsCRP greater than or ...
(Date:12/15/2009)... -- Medical researchers with EDP Biotech Corporation (EDP) ... technology for a simple blood test to detect ... success of its pre-clinical trials for the ColoMarker(TM) ... biomarker, CA11-19, and all aspects of its use. ... detect colon cancer in its earliest, most curable ...
(Date:12/15/2009)... -- Certified healthcare providers who have already immunized ... H1N1 flu virus may now offer the vaccine ... Health announced today. ,, Pennsylvania is expanding ... 3.2 million doses of vaccine have been allocated ... in the priority groups. ,, "Many certified providers ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research 26 Development 13756 1Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research 26 Development 13756 2Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research 26 Development 13756 3CBI Announces Multi Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum 55824 1CBI Announces Multi Stakeholder Collaboration Panel at Upcoming Effective Oncology Benefit Management Forum 55824 2New Non Drowsy CLARITIN 28R 29 12 Hour Gets Allergy Sufferers Through Their Busy Day 55822 1New Non Drowsy CLARITIN 28R 29 12 Hour Gets Allergy Sufferers Through Their Busy Day 55822 2New Non Drowsy CLARITIN 28R 29 12 Hour Gets Allergy Sufferers Through Their Busy Day 55822 3
... June 1, 2007 – Thallion Pharmaceuticals Inc.,(TSX: TLN) ... clinical trial investigating ECO-4601 in advanced cancer,patients was ... American,Society of Clinical Oncology (ASCO) Annual Meeting in ... of the study, 14,patients (ten colorectal, two ovarian, ...
... trial confirms that more patients,are alive today due ... analysis tracking,the outcome of patients with aggressive non-Hodgkin's ... therapy MabThera,(rituximab) over seven years ago has revealed ... pivotal phase III study has shown,that over half ...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 2MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 4
(Date:12/15/2009)... of the U.S. Senate to allow importation of ... more effective direct bulk purchasing of prescription drugs, ... industry controls the health reform debate, according Consumer ... Dorgan (D-ND) was a relatively modest proposal, far ... to directly negotiate discounts with drug manufacturers," said ...
(Date:12/15/2009)... SUNNYVALE, Calif., Dec. 15 Palo Alto ... Shinshu University has deployed its PA-4000 Series next-generation ... network and for enhanced visibility and control over ... University is a Japanese national university with eight ... in 1949 by integrating a number of academic ...
(Date:12/15/2009)... where all couples of reproductive age were evaluated, Italian ... The number of children born with cystic fibrosis decreases ... mutation carriers increases, a new study finds. , CF ... northeast Italy for many years. Since the 1990s, the ... number of infants born with CF. , Two different ...
(Date:12/15/2009)... cancer tests promised but not delivered ,, ... calls on Congress to ensure that healthcare reform ... currently required of insurance companies in 37 states. ... those segments of the population and individuals who ... men and men who have a family history ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will ... "it doesn,t matter whether there,s a public option. The ... option - give government authority over how your doctor ... social agenda by shifting billions of dollars from Medicare ... and local politicians." ,, Betsy McCaughey is ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... as annoying as a sore throat with the exception of ... is just moments away.// ,The American Academy of ... over-the-counter pain killer like acetaminophen, ibuprofen or naproxen. ,* Make ... or hard candy. ,* Gargle with salt water as many ...
... associated with spinal tumors has been developed by a ... vertebrae is a common feature in 5 to 10 ... ,Wade Wong, D.O.F.A.C.R, UCSD professor of radiology, ... spinal tumors from 28 patients before repairing the spine ...
... breakthrough in the field of nanotechnology, researchers have ... an anticoagulant. These blood compatible could ,revolutionize medical ... for renal failure patients. ,Furthermore, these ... applications that are ,not foreseen at the moment. ...
... may actually lull the consumer into a false sense ... case//. The European commission has got its act together ... labeling of sun lotions and its allied products. ... cues by captivatingly labeling a total protection message are: ...
... marathon kid of Orissa, declared that his health is normal. ... check up after he ran an astounding 65km earlier this ... Hospital at Bhubaneswar for a medical check up on the ... that coach Biranchi Das was exploiting the boy for his ...
... of PMS, those who have a caring and compassionate husband ... a new study. ,Time and over again, hormonal ... lethargy and pain associated with premenstrual syndrome or PMS. This ... for their wives can make matters worse. ,Women ...
Other Medicine News:Health News:Novel Technique To Revolutionize Treatment Of Spinal Tumors 2Health News:Heparin Based Nanoscale Materials Developed For Dialysis Treatment 2Health News:Marathon Kid Budhia’s Health Not Compromise 2Health News:Supportive Husbands Can Help Ease PMS 2
Inquire...
... Multifocal IOL was designed to provide a ... glasses in most situations. While distance vision ... to that of a single vision monofocal ... and about 19 in 20 people with ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
... Zeus Scientific, Inc. Measles test ... qualitative and quantitative detection of ... by the indirect fluorescent antibody ... determine or confirm recent infection ...
Medicine Products: